DENVER and GOLDEN, Colo., March 3 /PRNewswire/ -- ABR-Affinity BioReagents, a leading global antibody manufacturer, announced today the finalization of a reverse distribution agreement with Osenses Pty. Ltd., an Australian-based manufacturer of life science reagents. Further expanding its already extensive portfolio of 100% quality guaranteed research antibodies, ABR is now an authorized distributor of Osenses products in the U.S., Europe and Canada.
Osenses offers primary antibodies for experimental use in the areas of chemosensory receptors (olfactory, vomeronasal and trace amine-associated), and visual, auditory and transient receptors. According to Ken Wilczek, President of ABR-Affinity BioReagents, "Partnering with Osenses enhances our ability to offer experimental research tools to scientists who are active in the increasingly important realm of sensory neuronal research." Encompassing antibodies for olfactory receptors, market proteins and stem cells, the Osenses product line will round out ABR's existing antibody portfolio, which now comprises more than 36,000 quality-guaranteed antibodies and research reagents.
"This type of reverse distribution arrangement allows us to utilize our already strong sales channels to really help get these unique products into the hands of research scientists who are performing cutting edge research on a daily basis," noted Ken Wilczek, President of ABR. Beginning in 2005, ABR-Affinity BioReagents implemented a strategy to investigate and partner with select worldwide antibody suppliers who produce quality products for distribution through ABR into the U.S. Other reverse distribution partners currently include: Abnova, Ab Frontier, Antibody Shop, Good Biotech and Genesis.
About ABR-Affinity BioReagents
Founded in 1989 with world headquarters in Golden, Colorado,
ABR-Affinity BioReagents is a world leader in the manufacture and
distribution of monoclonal and polyclonal antibodies, kits, recombi
|SOURCE ABR-Affinity BioReagents|
Copyright©2008 PR Newswire.
All rights reserved